Balaji Steroids and Hormones 20mar2020
Balaji Steroids and Hormones 20mar2020
Balaji Steroids and Hormones 20mar2020
Brickwork Ratings downgrades the ratings of Rs. 20.00 Crores Balaji Steroids And
Hormones Pvt. Ltd. based on best available information, as the issuer did not cooperate.
Accordingly the rating for the said instrument is as under
Particulars
Amount (₹ Cr) Rating*
The rating was due for a review in Feb., 2020. BWR took up with the issuer to provide required
information over emails dated 02.03.2020 and 16.03.2020. Despite the best efforts of BWR to
get at least the minimum required information for a review, the entity has not provided the same.
In the absence of adequate information from the issuer/Company, BWR is unable to assess the
issuer’s/Company’s financial performance and its ability to service its debt and maintain a valid
rating. The company’s lender has reported irregularities in the conduct of bank loan accounts and
has confirmed over the call that the said account is classified as NPA.
Information availability risk is a key factor in the assessment of credit risk as generally,
noncooperation by the rated entities to provide required information for a review of the assigned
rating may also be accompanied by financial stress.
1
COMPANY PROFILE ( As available with BWR in Feb 2019)
M/s Balaji Steroids & Hormones Pvt Ltd was incorporated on 15th April 2010 at Pithampur,
Madhya Pradesh. It was formerly known as M/s Maikal Kanya Drugs Pvt Ltd . which was
formed on 15 th April, 2010. In 2013-14, the name of the company was changed to M/s Maikal
Kanya Nutrients Pvt Ltd.The company has started its trial production (Sampling) in April 2018
& will start its commercial activities from Mid of February 2019. The company was promoted by
Shri Pankaj Lulla & Shri Ashok Kumar Yadav. Later, there were changes in the management &
on 04th Nov, 2015 the new promoters of the company were Shri Sidharth P Aildasani, Shri
Akshay P Aildasani.The company will be specializing in the manufacturing and marketing of
corticosteroids, for the local and foreign market.
Rating History
NA NA
FB 20.00 BWR D FB 20.0 BWR BB-
(Downgraded) 0 Stable
Issuer Not Cooperating* (Assigned)
● General Criteria
2
Analytical Contacts Investor and Media Relations
Ushadevi V Dogra
Rating Analyst
+91 22 2831 1439 Ext: 650
[email protected] Liena Thakur
Assistant Vice President - Corporate Communications
Sushil Kumar Chitkara +91 84339 94686
Associate Director - Ratings [email protected]
B :+91 22 28 31 1416, + 91 22 2831 1439
[email protected]
ANNEXURE I
Balaji Steroids And Hormones Pvt. Ltd.
Details of Bank Facilities rated by BWR
Sl.No. Name of the Type of Facilities Long Short Total
Bank Term Term [₹ Cr]
[₹ Cr] [₹ Cr]
TOTAL 20.00
For print and digital media The Rating Rationale is sent to you for the sole purpose of dissemination
through your print, digital or electronic media. While it may be used by you acknowledging credit to
BWR, please do not change the wordings in the rationale to avoid conveying a meaning different from
what was intended by BWR. BWR alone has the sole right of sharing (both direct and indirect) its
rationales for consideration or otherwise through any print or electronic or digital media.
About Brickwork Ratings :Brickwork Ratings (BWR), a SEBI registered Credit Rating Agency,
accredited by RBI and empaneled by NSIC, offers Bank Loan, NCD, Commercial Paper, MSME ratings
and grading services. NABARD has empaneled Brickwork for MFI and NGO grading. BWR is accredited
by IREDA & the Ministry of New and Renewable Energy (MNRE), Government of India. Brickwork
Ratings has Canara Bank, a leading public sector bank, as its promoter and strategic partner. BWR has its
3
corporate office in Bengaluru and a country-wide presence with its offices in Ahmedabad, Chandigarh,
Chennai, Hyderabad, Kolkata, Mumbai and New Delhi along with representatives in 150+ locations.
DISCLAIMER Brickwork Ratings (BWR) has assigned the rating based on the information obtained
from the issuer and other reliable sources, which are deemed to be accurate. BWR has taken considerable
steps to avoid any data distortion; however, it does not examine the precision or completeness of the
information obtained. And hence, the information in this report is presented “as is” without any express or
implied warranty of any kind. BWR does not make any representation in respect to the truth or accuracy
of any such information. The rating assigned by BWR should be treated as an opinion rather than a
recommendation to buy, sell or hold the rated instrument and BWR shall not be liable for any losses
incurred by users from any use of this report or its contents. BWR has the right to change, suspend or
withdraw the ratings at any time for any reasons